脆性组氨酸三联体抗体
规格：1mg/1ml
英文名： FHIT
别名： fragile histidine triad; AP3A hydrolase; AP3A hydrolase fragile site 3p14.2; AP3Aase; Bis 5' adenosyl triphosphatase; Dinucleosidetriphosphatase; FRA 3B; FRA3B; Fragile histidine triad gene; Fragile h
分子量： 17kDa
储存液：0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glyce
克隆类型：Polyclonal
亚型：IgG
纯化方法：affinity purified by Protein A
**原：KLH conjugated synthetic peptide derived from human FHIT
交叉反应：Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit,
细胞定位：细胞浆
脆性组氨酸三联体抗体产品介绍：background: Glucose-6-phosphatase (G6Pase) is a multi-subunit integral membrane protein of the endoplasmic reticulum that is composed of a catalytic subunit and transporters for G6P, inorganic phosphate, and glucose. This gene (G6PC) is one of the three glucose-6-phosphatase catalytic-subunit-encoding genes in human: G6PC, G6PC2 and G6PC3. Glucose-6-phosphatase catalyzes the hydrolysis of D-glucose 6-phosphate to D-glucose and orthophosphate and is a key enzyme in glucose homeostasis, functioning in gluconeogenesis and glycogenolysis. Mutations in this gene cause glycogen storage disease type I (GSD1). This disease, also known as von Gierke disease, is a metabolic disorder characterized by severe hypoglycemia associated with the accumulation of glycogen and fat in the liver and kidneys.[provided by RefSeq, Feb 2011] Function: Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it is the key脆性组氨酸三联体抗体 enzyme in homeostatic regulation of blood glucose levels. Subunit: Homodimer. Subcellular Location: Cytoplasm. Tissue Specificity: Low levels expressed in all tissues tested. Phospho-FHIT observed in liver and kidney, but not in brain and lung. Phospho-FHIT undetected in all tested human tumor cell lines. DISEASE: Glycogen storage disease 1A (GSD1A) [MIM:232200]: A metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. Patients manifest a wide range of clinical symptoms and biochemical abnormalities,脆性组氨酸三联体抗体 including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Contains 1 HIT domain. Gene ID: 2538 Database links: Entrez Gene: 403492 Dog Entrez Gene: 2538 Human Entrez Gene: 14377 Mouse Entrez Gene: 25634 Rat SwissProt: O19133 Dog SwissProt: P35575 Human SwissProt: P35576 Mouse SwissProt: P43428 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 脆性组氨酸三联体（FHIT）作为肿瘤抑制因子发挥作用，其基因的突变和缺失与人类一系列肿瘤的发生和发展密切相关。这些肿瘤发生部位包括肺、头颈部、乳腺、结肠、胃以及胰腺。
脆性组氨酸三联体抗体产品应用：WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
研究领域：肿瘤 **学
储存条件： Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
来源： Rabbit
外观： Lyophilized or Liquid